Navigation Links
Chiasma to Present at the UBS Global Life Sciences Conference

NEW YORK and JERUSALEM, Sept. 14, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that Fredric Price, Chiasma's Chairman & CEO, will present an overview of the Company at the UBS Global Life Sciences Conference at the Grand Hyatt, New York, New York, on Monday, September 19, 2011 at 1:30 PM.

Chiasma's investigational new drug Octreolin™ is an oral form of octreotide acetate being developed first for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.  The Company successfully completed 4 clinical studies with Octreolin in healthy volunteers, having established a pharmacokinetics profile similar to that of subcutaneously injected octreotide acetate.  In addition, Octreolin demonstrated the ability to reduce growth hormone.  No serious adverse safety events were reported in any of the studies.  A trial in patients will commence in October 2011.  Chiasma intends to file an NDA using the 505(b)(2) regulatory pathway in the US and its EMA equivalent, the Hybrid Application in Europe.

Octreolin is also being developed as a chronic treatment for patients with Portal Hypertension (PHT); a Phase 2 proof of concept trial for this new orphan indication (no drugs are approved for PHT in the US) was initiated in September 2011.  The Company has a pipeline of products that are currently in preclinical development including one in renal disease that will enter the clinic in mid-2012.

About Chiasma

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small molecules into the portal system and then to the systemic circulation.  The TPE technology not only enables their being converted from injectable to oral, but importantly can result in the development of new indications.

Chiasma is a Delaware corporation with a 100% owned Israeli subsidiary.  It is backed by MPM Capital, ARCH Venture Partners, F-2 Ventures and 7 Med Health Ventures.

Additional information can be found at:

Forward-Looking Statements

This press release contains forward-looking statements about the business, goals and prospects of Chiasma, Inc., including, without limitation, statements about the development of drugs in the TPE system.  These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements.  Chiasma is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chiasmas Octreolin™ (Oral Octreotide) Shown to Inhibit Growth Hormone in Healthy Subjects
2. Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products
3. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Heska to Present at LD MICRO Invitational on September 22, 2011
6. Isis Pharmaceuticals to Present at the UBS Global Life Sciences Conference
7. BioMarin to Present at the UBS Global Life Sciences Conference
8. Henry Schein to Present at the CL King 9th Annual Best Ideas Conference 2011
9. PDL BioPharma to Present at Upcoming Investor Conferences
10. Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
11. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
Post Your Comments:
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
Breaking Medicine Technology:
(Date:11/27/2015)... Canada (PRWEB) , ... November 28, 2015 , ... There ... do we outperform our billings from last year? , This question has not been ... organizations are coming to the retirement age and the younger workforce don’t share the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid ... America. As people age, more care is needed, especially with Alzheimer’s, dementia and ... professionals are being overworked. The forgotten part of this equation: 80 percent of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special ... 10% off of their purchase of lice treatment product. In addition, customers will receive ... a company spokesperson. “Finding lice is a sure way to ruin the holidays, so ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges faced ... and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities ... by parents and bring advice from parenting experts within their reach. As a ...
Breaking Medicine News(10 mins):